CellSource CoTSE:4880 -2.15%69 PE Ratio without NRI is 65.98 as of Jul. 09, 2026, which is 25% below its 10-year median of 87.93. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 266 Biotechnology companies, CellSource Co ranks worse than 79.32% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-09), CellSource Co's share price is 円319.00.
CellSource Co's EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 was 円4.84. Therefore, CellSource Co's PE Ratio without NRI for today is 65.98.
During the past 9 years, CellSource Co's highest PE Ratio without NRI was 479.15. The lowest was 24.59. And the median was 87.93.
During the past years, CellSource Co's highestPE Ratio (TTM) was 957.41. The lowest was 23.78. And the median was 84.94.
CellSource Co's
EPS (Diluted) for the
six
months ended in Apr. 2026 was 円3.58.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 was 円3.56.
CellSource Co's EPS (Basic) for the
six
months ended in Apr. 2026 was 円3.59.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was 円3.57.
CellSource Co (TSE:4880) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
CellSource Co PE Ratio without NRI Related Terms
CellSource Co PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for CellSource Co's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison
For the Biotechnology subindustry, CellSource Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where CellSource Co's PE Ratio without NRI falls into.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
CellSource Co's PE Ratio without NRI for today is calculated as
CellSource Co's Share Price of today is 円319.00.
For company reported semi-annually, CellSource Co's EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円4.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
CellSource Co (TSE:4880) has a PE Ratio without NRI of 65.98 as of Jul. 09, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on CellSource Co and its competitors. This is 25% below median its historical median of 87.93. Over the past decade, CellSource Co's PE Ratio without NRI has ranged from 24.59 to 479.15. According to the industry distribution chart, CellSource Co ranks #211 out of 266 companies in the Biotechnology industry, placing it in the top 79.3%.
Is CellSource Co's PE Ratio without NRI too high?
CellSource Co's current PE Ratio without NRI of 65.98 is 25% below median its 10-year median of 87.93. Over the past 10 years, this metric has ranged from a low of 24.59 to a high of 479.15. The Biotechnology industry median PE Ratio without NRI is 25.30. CellSource Co's value of 65.98 is 160.8% above this industry median. Based on the distribution chart, CellSource Co ranks #211 out of 266 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #211 out of 266 companies for PE Ratio without NRI. This places CellSource Co in the lower half of its industry. The industry median PE Ratio without NRI is 25.30. CellSource Co's value of 65.98 is 160.8% above this benchmark. Historically, CellSource Co's own PE Ratio without NRI has ranged from 24.59 to 479.15 over the past decade. While the company's 10-year median is 87.93 vs. the industry median of 25.30, CellSource Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.30, based on 266 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current PE Ratio without NRI of 65.98 is 160.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current PE Ratio without NRI is 65.98, which is 25% below median its own 10-year median of 87.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current PE Ratio without NRI is 65.98, which is 25% below median its 10-year median of 87.93 and 160.8% above the Biotechnology industry median of 25.30. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current PE Ratio without NRI is 65.98 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
PE Ratio without NRI: 65.98 (25% below median its 10-year median of 87.93)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
Industry Position: 160.8% above the Biotechnology median (#211 of 266)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
